FDA Brief

Warning letters Drugs

FDA warning letter to

DEPQ Internacional S. de R.L de C.V.

High riskIssued Mar 18, 2021Posted Mar 23, 2021Center for Drug Evaluation and Research

FDA says DEPQ Internacional's hand sanitizers had far less active ingredient than labeled without FDA approval and with false labeling.

What happened

FDA tested batches of Cleanhumans Hand Sanitizer, dgreen ADVANCED HAND SANITIZER ANTIBACTERIAL GEL and dgreen ADVANCED HAND SANITIZER Alcohol Free after the products were detained and refused admission at the U.S. border; the products were declared as made at DEPQ Internacional's San Luis Potosí facility. The labels stated 60% ethanol for two products and 10% benzalkonium chloride for the alcohol-free product, but FDA found 1.5–1.7% ethanol in four samples and 0.7% and 1.5% benzalkonium chloride in two samples. FDA cited the products as adulterated (below labeled strength), said quality assurance did not meet current good manufacturing practice (CGMP), and cited unapproved new drug and misbranding violations; FDA placed all firm drugs on Import Alert 66-78 on July 31, 2020.

What FDA found

  1. The ethanol-labeled hand sanitizers contained 1.5–1.7% ethanol, not the labeled 60%, so their strength was below what the label said.

    Section 501(c) of the FD&C Act, 21 U.S.C. 351(c)
  2. The alcohol-free hand sanitizer contained 0.7% and 1.5% benzalkonium chloride in two samples, not the labeled 10%, so its strength was below what the label said.

    Section 501(c) of the FD&C Act, 21 U.S.C. 351(c)
  3. The low active ingredient levels showed that quality assurance at the facility was not working under current good manufacturing practice (CGMP).

    Section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
  4. The products were marketed as drugs without FDA approval and did not meet the conditions for nonprescription marketing without an approved application, including because their formulations used chlorhexidine gluconate and citric extracts.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d); section 505G
  5. The labels were false or misleading because they stated much higher active ingredient amounts than testing found.

    Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  6. Cleanhumans also lacked a U.S. address or phone number for serious adverse event reports, and the products did not meet the requirements for nonprescription drugs without an approved application.

    Sections 502(ee) and 502(x) of the FD&C Act, 21 U.S.C. 352(ee) and 352(x)

What FDA wants

FDA asks for a detailed investigation of the subpotency, a list of all raw materials and suppliers, a list and full reconciliation of hand sanitizer batches shipped to the U.S., and complete batch records, with a written response within 15 working days. If the firm cannot respond within 15 working days, it must state reasons and a completion schedule.

Who should pay attention

  • U.S. distributors and retailers that buy hand sanitizer from Mexican manufacturers
  • brands or importers sourcing hand sanitizers from DEPQ Internacional
  • healthcare personnel and consumers who rely on labeled hand sanitizer strength

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk